Cubist Presents Detailed Results from Positive Phase 3 Trials of Ceftolozane/Tazobactam at 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Cubist Presents Detailed Results from Positive Phase 3 Trials of Ceftolozane/Tazobactam at 2014 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

[Business Wire] – Cubist Pharmaceuticals, Inc. today announced the first detailed results from positive pivotal Phase 3 clinical trials of its antibiotic candidate ceftolozane/tazobactam in development to treat serious infections including complicated ur more

View todays social media effects on CBST

View the latest stocks trending across Twitter. Click to view dashboard

See who Cubist is hiring next, click here to view

Share this post